Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the clinical outcomes following resumption of
dosing (re-challenge) with Imatinib plus best supportive care versus placebo plus best
supportive care in patients with advanced/incurable Gastrointestinal Stromal Tumors following
failure of prior imatinib and sunitinib therapies.